Skip to main content

Table 2 Changes in clinical parameters for oMGD patients between before and 4 or 8 weeks after the onset of maxacalcitol treatment

From: Clinical safety and efficacy of vitamin D3 analog ointment for treatment of obstructive meibomian gland dysfunction

Parameter

Pretreatment

4 weeks

8 weeks

Ocular symptoms

6.9 ± 2.5

4.0 ± 1.2 (0.001)

2.2 ± 1.3 (<0.001)

Plugging of gland orifices (0–3)

1.8 ± 0.8

0.9 ± 0.7 (0.070)

0.4 ± 0.5 (<0.001)

Lid margin irregularity (0–2)

1.0 ± 0.6

0.8 ± 0.4 (0.597)

0.8 ± 0.4 (0.597)

Lid margin vascularity (0–3)

1.3 ± 0.5

0.6 ± 0.5 (0.020)

0.6 ± 0.5 (0.020)

MCJ replacement (0–3)

1.0 ± 0.6

0.8 ± 0.4 (0.633)

0.7 ± 0.5 (0.197)

BUT (s)

2.9 ± 1.4

4.2 ± 1.7 (0.163)

5.4 ± 2.2 (0.030)

SPK score (0–9)

0.5 ± 0.5

0.3 ± 0.5 (0.519)

0.5 ± 0.0 (0.011)

Meibum grade (0–3)

2.0 ± 1.0

1.3 ± 0.8 (0.105)

0.8 ± 0.8 (0.020)

Schirmer test value (mm)

6.5 ± 1.1

6.9 ± 1.0 (0.548)

6.6 ± 1.1 (0.974)

Mean meibomian gland area (%)

24.0 ± 8.3

27.7 ± 7.3 (0.399)

32.8 ± 7.5 (0.017)

  1. Values in parentheses are P values for comparison with the corresponding pretreatment data (one-way ANOVA followed by Dunnett’s test)